Skip to Content, Navigation, or Footer.
Friday, May 2, 2025
The Emory Wheel

From Our Sponsors

Exploring the Potential of B7-33 Peptide in Fibrosis and Vascular Research

This content was paid for by an advertiser. The Emory Wheel newsroom was not involved in creating this content.

The B7-33 peptide, a synthetic analog of the B-chain of relaxin-2, has garnered attention in scientific circles due to its distinctive structural attributes. This peptide is believed to offer a more targeted approach to receptor activation compared to its parent hormone, relaxin-2. The unique properties of B7-33 suggest its potential utility in various research domains, particularly those focusing on fibrosis and vascular function. 

  

Screenshot 2025-04-24 at 20.10.55.png

Structural Characteristics and Receptor Interaction 

  

B7-33 is designed as a single-chain peptide, simplifying the complex two-chain structure of native relaxin-2. This streamlined configuration is hypothesized to enhance its stability and facilitate more practical synthesis. The peptide is believed to interact selectively with the relaxin family peptide receptor 1 (RXFP1), initiating intracellular signaling pathways that could be pivotal in modulating fibrotic processes and vascular tone. 

  

RXFP1 is a G-protein-coupled receptor (GPCR) associated with various physiological functions, including extracellular matrix remodeling, vasodilation, and inflammatory regulation. Upon activation, RXFP1 influences signaling pathways such as phosphoinositide 3-kinase (PI3K)/Akt and extracellular signal-regulated kinases (ERK), which may be involved in regulating cellular proliferation and apoptosis. 

  

Fibrosis Research 

  

Fibrosis, characterized by excessive deposition of extracellular matrix components, poses significant challenges across multiple organ systems. Research indicates that B7-33 might activate the extracellular signal-regulated kinase (pERK) pathway without concurrently stimulating the cyclic adenosine monophosphate (cAMP) pathway. This selective pathway activation is thought to promote the expression of matrix metalloproteinases (MMPs), enzymes that degrade collagen and other matrix proteins, thereby potentially mitigating fibrotic tissue accumulation. 

  

Investigations purport that in experimental models, B7-33 exposure may reduce fibrotic tissue formation. For instance, studies suggest that in cardiac models, the peptide might decrease interstitial collagen deposition, which is often associated with improved cardiac function. Similarly, in pulmonary research, B7-33 is theorized to attenuate lung fibrosis, potentially preserving respiratory function. 

  

The peptide's potential impact on fibrosis could extend to multiple organs, including the liver and kidneys, where excessive extracellular matrix accumulation contributes to disease progression. In hepatic research, B7-33 seems to influence hepatic stellate cells, which play a paramount role in liver fibrosis, potentially reducing the deposition of fibrotic tissue. Likewise, renal fibrosis, a hallmark of chronic kidney disease, may also be influenced by the peptide's interaction with RXFP1, suggesting possible avenues for further study. 

  

Vasoprotective Research 

  

Beyond its anti-fibrotic implications, B7-33 is also being explored for its possible vasoprotective properties. The peptide's interaction with RXFP1 is hypothesized to induce vasodilation by relaxing vascular smooth muscle cells. This mechanism could lead to decreased vascular resistance and improved blood flow. Such properties may have implications in conditions characterized by vascular dysfunction, such as hypertension and atherosclerosis. 

  

Moreover, the peptide's potential to modulate inflammatory pathways is under investigation. Chronic inflammation is a known contributor to vascular diseases, and B7-33's potential to influence these pathways might further enhance its vasoprotective profile. It has been hypothesized that B7-33 might reduce endothelial cell activation, thereby limiting the recruitment of inflammatory cells and minimizing vascular damage. 

  

Another interesting avenue of research involves the peptide's potential impact on angiogenesis. Emerging data suggests that RXFP1 activation may contribute to the regulation of renewed blood vessel formation. If B7-33 influences this process, it could hold implications for wound healing, tissue regeneration, and even cancer research, where aberrant angiogenesis plays a crucial role. 

  

Implications in Cardiovascular Research 

  

B7-33's multifaceted actions position it as a candidate for cardiovascular research. Its potential to reduce cardiac fibrosis and improve myocardial compliance is of particular interest. Research indicates that by promoting collagen degradation and inhibiting fibroblast proliferation, B7-33 might contribute to the preservation of cardiac architecture and function. 

  

Additionally, the peptide's vasodilatory properties could be useful in the context of conditions like hypertension, where increased vascular resistance is a primary concern. Investigations purport that by enhancing arterial flexibility and reducing stiffness, B7-33 might aid in the context of optimal blood pressure levels. 

  

In heart failure models, RXFP1 activation has been linked to improved cardiac function and reduced hypertrophy. B7-33's potential to selectively activate RXFP1 without engaging other relaxin-mediated pathways could provide a novel research tool for exploring cardiac remodeling mechanisms. 

  

Potential in Pulmonary Research 

  

In pulmonary research, B7-33's anti-fibrotic potential regarding lung fibrosis are being explored. The peptide's potential to modulate extracellular matrix turnover suggests it might play a role in preserving lung elasticity and function. This is particularly relevant in conditions such as idiopathic pulmonary fibrosis, where excessive fibrotic tissue impairs respiratory efficiency. 

  

Furthermore, B7-33's potential role in modulating pulmonary vascular function could be of interest in conditions like pulmonary hypertension. The peptide's hypothesized vasodilatory impact on pulmonary arteries might contribute to reduced vascular resistance and improved oxygen exchange efficiency. 

  

Exploration in Oncology and Regenerative Science 

  

The role of RXFP1 activation in oncology and regenerative science remains an emerging field of interest. Some studies suggest that relaxin peptides may influence tumor progression, particularly in the context of extracellular matrix remodeling. B7-33's selective RXFP1 activation might offer a unique perspective on how tumor microenvironments interact with surrounding stromal tissues. 

  

In regenerative science, B7-33's potential to influence fibroblast activity and collagen turnover suggests possible implications for tissue repair and wound healing. Given that fibrosis is often a limiting factor in regenerative processes, exploring the peptide's potential to modulate scarring and tissue remodeling might yield valuable insights. 

  

Considerations for Future Research 

  

While the preliminary findings surrounding B7-33 are promising, it is essential to approach these results with cautious optimism. The exact mechanisms underlying the peptide's selective pathway activation and its long-term impacts remain to be fully elucidated. Further research is necessary to determine the optimal parameters for its application in various experimental settings. 

  

Additionally, understanding the peptide's pharmacokinetics and potential interactions with other signaling molecules will be crucial in delineating its role within the broader context of fibrotic and vascular research. Future studies may seek to investigate its stability, receptor binding dynamics, and response relationships in different experimental models. 

  

Conclusion 

  

The B7-33 peptide represents a compelling subject in the study of fibrosis and vascular function. Its unique structural design and selective receptor interactions offer a novel approach to modulating complex biological pathways. As research progresses, B7-33 may provide valuable insights into the mechanisms of tissue remodeling and vascular integrity, potentially informing future research strategies in these domains. Whether in cardiovascular research, pulmonary studies, or broader applications in oncology and regenerative science, the peptide continues to be an intriguing area for ongoing scientific exploration. Scientists interested in this peptide may go here 

  

References 

  

[i] Samuel, C. S., Royce, S. G., Hewitson, T. D., Denton, K. M., Cooney, T. E., Bennett, R. G., & Bathgate, R. A. D. (2017). Anti-fibrotic actions of relaxin. British Journal of Pharmacology, 174(10), 962–976. https://doi.org/10.1111/bph.13700 

  

[ii] Zhang, S., McDonald, J., Hossain, M. A., Shabanpoor, F., Chan, L. J., Bathgate, R. A. D., & Wade, J. D. (2023). A lipidated single-B-chain derivative of relaxin exhibits improved in vitro serum half-life. Frontiers in Chemistry, 11, 1134567. https://doi.org/10.3389/fchem.2023.1134567 

  

[iii] Ng, H. H., Leo, C. H., Prakoso, D., Qin, C. X., Ritchie, R. H., & Parry, L. J. (2017). B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin) in aged and diabetic mice. Pharmacological Research, 117, 32–39. https://doi.org/10.1016/j.phrs.2016.12.019 

  

[iv] Hossain, M. A., Rosengren, K. J., Haugaard-Jönsson, L. M., Zhang, S., Layfield, S., Ferraro, T., ... & Wade, J. D. (2016). The single-chain relaxin mimetic, B7-33, promotes angiogenesis and reduces myocardial fibrosis. Journal of the American Chemical Society, 138(5), 1643–1652. https://doi.org/10.1021/jacs.5b12900 

  

[v] Chan, L. J., Rosengren, K. J., Layfield, S., Bathgate, R. A. D., & Samuel, C. S. (2020). B7-33, a functionally selective relaxin receptor 1 agonist, confers acute cardioprotection and limits myocardial infarction–related adverse remodeling in mice. Journal of the American Heart Association, 9(10), e015748. https://doi.org/10.1161/JAHA.119.015748